Bayer AG
Bayer AG works on 25 rare diseases tracked on Trial Friend, including Alport Syndrome, Aplastic Anemia, ATTR Amyloidosis (Transthyretin Amyloidosis) and 22 more, with 27 recruiting clinical trials and 10 FDA-approved rare disease drugs.
Bayer is a global pharmaceutical and life sciences company with a growing oncology portfolio that includes Vitrakvi (larotrectinib), the first FDA-approved treatment specifically targeting NTRK gene fusions across solid tumor types regardless of where the cancer originated. Bayer also maintains active clinical programs in rare hematologic and cardiovascular conditions.
Focus areas at Bayer AG
Within its broader pharmaceutical portfolio, Bayer AG has active clinical trial programs and drug development efforts across 25 rare diseases, including Alport Syndrome, Aplastic Anemia, ATTR Amyloidosis (Transthyretin Amyloidosis), Cholangiocarcinoma, Chronic Graft-versus-Host Disease, and 20 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Bayer AG, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Bayer AG is headquartered in Leverkusen, Germany, founded in 1863, publicly traded under the ticker symbol BAYN. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Bayer AG Drug Pipeline
Bayer AG has 27 active clinical trials across 5 development stages, with 27 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline includes all of Bayer AG's active interventional trials, not only those targeting rare diseases. We show the full pipeline because a company's broader research activity, therapeutic expertise, and development infrastructure directly shape its ability to advance rare disease programs. A strong overall pipeline often signals deeper clinical operations, faster enrollment capabilities, and greater commitment to bringing new treatments to patients.
Bayer AG Clinical Trials (27)
Active and recruiting clinical trials sponsored by Bayer AG, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Bayer AG FDA-Approved Drugs (10)
Medications developed or marketed by Bayer AG that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| PRAZIQUANTEL Anthelmintic [EPC] | Biltricide oral | Dec 29, 1982 | |
| GADOBUTROL Gadolinium-based Contrast Agent [EPC] | Gadavist intravenous | Mar 14, 2011 | |
| ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST | Natazia | May 6, 2010 | |
| LAROTRECTINIB Kinase Inhibitor [EPC] | VITRAKVI oral, oropharyngeal | Nov 26, 2018 | |
| DROSPIRENONE AND ETHINYL ESTRADIOL | Yaz | Mar 16, 2006 |
Bayer AG Trial Locations
Bayer AG clinical trials are running at 570 sites in 39 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (25)
Diseases targeted by Bayer AG's clinical trial and drug development programs
Alport Syndrome is a genetic disorder that causes progressive damage to the kidneys, ears, and eyes due to defects in a type of collagen that provides structure and flexibility to tissues. The conditi...
Aplastic anemia is a rare bone marrow failure syndrome characterized by pancytopenia resulting from absent or severely reduced hematopoiesis. Approximately half are immune-mediated, while others resul...
ATTR amyloidosis is a rare progressive disease where abnormal transthyretin protein accumulates as amyloid deposits in the heart, nerves, and other organs. It can be inherited (hereditary ATTR) or dev...
Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive fluid (bile) from the liver to the small intestine. It can occur inside the liver (...
Chronic graft-versus-host disease is an immune-mediated complication after allogeneic stem cell or bone marrow transplant, in which donor immune cells attack the recipient's tissues. It can affect the...
Cystic fibrosis is an autosomal recessive genetic disorder affecting the CFTR protein, which normally regulates chloride transport. Defective CFTR causes thick, sticky secretions in the lungs and dige...
Patient Resources
Organizations and resources related to Bayer AG's rare disease focus areas
Frequently Asked Questions About Bayer AG
Common questions about Bayer AG's rare disease programs, clinical trials, and treatments.